Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRD1 | O95696 | 2/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606960 | 0.85 | ADRB3 (0.45) | ADRB3ADRB2ADRB1 | |
| SCHEMBL4607235 | 0.84 | ADRB3 (0.45) | ADRB3LMNAADRB2ADRB1ALDH1A1 | |
| SCHEMBL2946701 | 0.82 | ALDH1A1 (0.47) | ADRB3ADRB2ADRB1ALDH1A1 | |
| SCHEMBL2942905 | 0.82 | ALDH1A1 (0.47) | ADRB3ADRB2ADRB1ALDH1A1 | |
| SCHEMBL4605935 | 0.81 | ADRB3 (0.46) | ADRB3ADRB2ADRB1KMT2AALDH1A1 | |
| SCHEMBL2942032 | 0.81 | ADRB3 (0.47) | ADRB3ADRB2ADRB1 | |
| SCHEMBL2198509 | 0.81 | ADRB3 (0.49) | ADRB3ADRB2ADRB1 | |
| SCHEMBL14185303 | 0.80 | ADRB3 (0.42) | ADRB3ADRB2ADRB1 | |
| Trifluoroacetic Acid SCHEMBL4608301 | 0.80 | ADRB3 (0.44) | ADRB3LMNAADRB2ADRB1ALDH1A1 | |
| SCHEMBL2943640 | 0.80 | ADRB3 (0.46) | ADRB3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943229-A1 | BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| WO-2007048842-A1 | BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007048842-A1 | BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | TRIM24 4310/4885ADRB3 2/4885LMNA 880/4885 |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | ADRB3, ADRB1, ADRA1B | TRIM24 4114/4885ADRB3 1/4885LMNA 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.